Celase GMP
Celase GMP
| Name | Qty | Size | Catalog Number |
|---|---|---|---|
| Celase GMP | 1 | 35 mg | 1235-01 |
Celase GMP is a proprietary, blended proteolytic enzyme designed for efficient, gentle and reproducible in vitro dissociation of nucleated cells from adipose tissue.
- Now available as a standalone product
- Foundational and versatile for all research programs
- Eliminates time consuming, costly bridging studies
- Pack Size: 1 vial, 35 mg
- Samples: limited quantities available upon request
DISTRIBUTION PARTNERS
LABELING AND SPECIFICATIONS
TISSUE DISSOCIATION PROTOCOLS
PRODUCT COMPARISONS
- White Paper: Cytori Celase or SERVA Collagenase NB?
Celbrush
Celbrush
| Name | Qty | Size | Catalog Number |
|---|---|---|---|
| Celbrush 3 mL | 1 | 3 mL | 503/CRS |
| Celbrush 3 mL Starter Kit | 1 | 3 mL Kit | 521/CRS |
| Celbrush 10 mL | 1 | 10 mL | 510/CRS |
| Celbrush 10 mL Starter Kit | 1 | 10 mL Kit | 520/CRS |
Celbrush is a stainless steel surgical instrument for precise delivery of fat tissue micro droplets. The thumb-brush design gives the Celbrush a mechanical advantage that minimizes the build-up of pressure, and provides superior tactile feedback during fat tissue dispersion. This allows the surgeon, with a simple brush of his or her thumb, to exactly control the micro droplet fat tissue volume injected into the defect area without ever looking at the syringe, while simultaneously avoiding transient syringe obstruction and over-filling of the defect space.
For each full brush of the operator’s thumb, the Celbrush 3 mL and Celbrush 10 mL instruments deliver approximately 0.15 mL and 0.50 mL of fat tissue, respectively.
LABELING AND SPECIFICATIONS
DISTRIBUTION PARTNERS
- Karam Medical (Spain Only)
- SURE Medical (Netherlands Only)
Stemsource Cell Bank
Stemsource Cell Bank
| Name | Catalog Number |
|---|---|
| StemSource 900/MB Tissue Processor | 900/MB |
| StemSource Procedure Set | 920/MB |
| StemSource Bank Service Plan, 1-Year | 0962-00 |
| StemSource Bank Service Plan, 3-Year | 0963-11 |
The StemSource® Cell Bank is a customized, turn-key, GTP-compliant, turn-key technology designed to provide a high degree of safety and quality in cryopreserving and recovering viable, functioning Adipose Derived Regenerative Cells (ADRCs). The StemSource Cell Bank consists of a Tissue Processor, Procedure Set, Web-Based Processing and Data Management Application, Standard Operating Procedures, and additional equipment such as liquid nitrogen dewar storage tanks, control rate freezers, and biological safety cabinets.
LABELING AND SPECIFICATIONS
EARLY ACCESS PROGRAM SUPPLIES
Early Access Programs provide biopharmaceutical companies with a way to allow compliant and ethical access to their pre-approval medicines to help patients with unmet medical needs. Access is provided in response to physician requests when no alternative treatment options are available. The source of medicine funding varies by country and may be derived from the government, hospital, insurer, and/or patient.
The name ‘Early Access Program’ is analogous to other terms often used for similar programs such as: named patient, special access, expanded access, managed access, early use, compassionate use, single patient IND, treatment IND, special therapeutic, and cohort supply. The names used vary by company, country, program, and regulatory area.
Cytori’s Early Access Program across the EU, Middle East and Latin America (excluding Chile) is intended to provide patients with hand manifestations of systemic scleroderma early access to Habeo Cell Therapy™. These patients typically are unable to participate in ongoing clinical trials due to amongst others lack geographic proximity to a trial site.
Companies such as Cytori which are authorized to distribute unlicensed medicines via an Early Access Program are not involved in the patient-doctor relationship. All information regarding patients is controlled under specific privacy and data protection legislation. Cytori can only distribute where permitted to do so and only in response to an unsolicited information or product supply request.
Cytori’s Early Access Program distributor is myTomorrows:
myTomorrows
Anthony Fokkerweg 61
1059 CP Amsterdam
The Netherlands
Tel: +31 88 525 38 88
Website: http://mytomorrows.com
For product-related questions:
Ozerk Akgun, MD, PhD
Ozerk.akgun@mytomorrows.com
+31 88 525 38 44
Please note: “This contact information is intended for healthcare professionals only.”